The global nasal allergy treatment market, valued at USD 6.6 billion in 2022, is expected to witness steady growth, projected to expand at a compound annual growth rate (CAGR) of 6.7% in the upcoming years. This growth is driven by the increasing prevalence of nasal allergies, including allergic rhinitis, which currently holds a substantial 65.8% share in the market by disease type. The rise in environmental pollutants, seasonal allergies, and greater awareness of treatment options are factors fueling this market expansion.
According to a recent study by Future Market Insights, the demand for nasal allergy treatments is on the rise as patients seek more accessible and effective remedies for managing their conditions. The report highlights that allergic rhinitis remains the dominant segment, with a substantial market share and a robust growth outlook, signaling ongoing investment and innovation within the market.
In such circumstances, awareness is crucial, therefore webinars and campaigns aid in spreading the message. One such example is a health-focused week called allergy awareness week, which was established by the charity Allergy UK and is observed every year during a week chosen by the organization. It occurs in the year 2023 from April 24 to April 30. This week is dedicated to educating people about allergies and providing assistance and support to those who suffer from allergic disorders.
Key Takeaways:
- Allergic Rhinitis is the leading segment among other diseases, and holds around 65.8% market value share in 2022, owing to higher rates of identified cases.
- The tablets/Capsules segment is set to lead in terms of the form of nasal allergy treatment with a projected market value share of around 33.6% by 2033, with respect to the physical and chemical attributes.
- By prescription type, the widely adopted is OTC drugs as they are easily available without prescription and also the commonly prescribed drugs for allergy can be easily availed from drug stores. OTC by prescription type held a market share of 76.3% in the year 2022.
- Multiple treatments are available but Antihistamines hold a significant share of 46.0% in the treatment segment as they can successfully treat a wide range of allergic reaction symptoms.
- By distribution channel, hospital pharmacies held a share of around 35.9% in 2022 due to the easy accessibility of licensed and approved medications.
- North American region dominated the global market with the U.S. contributing 92.4%value share to the North American market, owing to the prevalence of nasal allergies in the region.
What are the Key Opportunities for the Manufacturers Operating in the Global Market?
Globally, the prevalence of hay fever/allergic rhinitis was registered at ~35%, which is gaining the attraction of manufacturers to develop a specific treatment for this indication. This creates an enormous opportunity for the manufacturer to explore the nasal allergy treatment market. The life science industry has set foot into the pharmaceutical industry giving rise to multiple biopharma companies that have proven technology and advanced treatment options that are exclusive and received approval, this gives healthcare specialists to rely upon these new treatment options.
For instance, the main method for treating people with sensitivities to aeroallergens is subcutaneous immunotherapy (SCIT). Subcutaneous immunotherapy (SCIT), a revolutionary treatment for allergic illnesses, reduces discomfort while modifying allergic disease by concentrating on the underlying immunological mechanism. In numerous well-controlled clinical trials, its effectiveness and safety have been proven in the treatment of allergies, allergic rhinitis/rhinoconjunctivitis, asthma, and hypersensitivity to stinging insects.
Overall, it is anticipated that the market for nasal allergy treatments will rise over the coming years as more research and development are put into creating fresh, efficient treatment choices.
Competitive Landscape
Increase in number of pipeline products and approval by the regulatory bodies, along with merger and acquisition by key players in different regions, are key differentiating strategies that nasal allergy treatment manufacturers are adopting.
- In Aug 2018, two products from HAL Allergy Group received marketing clearance in Germany. They include SUBLIVAC® Birch 40.000 AUN/ml and SUBLIVAC® Trees 40.000 AUN/ml.
- Nestle Health Science announced in August 2020 that it will purchase the food allergy product line of Aimmune Therapeutics, Inc. The agreement should be finalised by the fourth quarter of 2020.
Similarly, recent developments related to companies manufacturing nasal allergy treatment drugs have been tracked by the team at Future Market Insights. These are available in the full report.
Key Companies Profiled
- Merck KGaA
- Johnson & Johnson
- Allergopharma
- Sanofi SA
- McNeil Consumer Healthcare,
- Genentech Inc.
- GlaxoSmithKline PLC
- Leti Pharma,
- Alerpharma S.A
- Allergan, Inc.
- Meda Pharmaceuticals, Inc
- Novartis International AG
- Bausch Health Companies Inc.
- Allergopharma
- ALK Abello
- Stallergenes Greer
- Allergy Therapeutics
- Aimmune Therapeutics
- Biomay AG
- HAL Allergy Group
- Bayer
- AstraZeneca
Key Market Segments Covered in the Nasal Allergy Treatment Industry Research
By Disease Type:
- Allergic Rhinitis
- Seasonal Allergic Rhinitis
- Perennial Allergic Rhinitis
- Non-Allergic Rhinitis
- Infectious Rhinitis
By Form:
- Tablets/Capsules
- Liquid
- Creams & Lotions
- Drops
- Spray
By Prescription Type:
- OTC
- Prescription based
By Route of Administration:
- Oral
- Intranasal
- Sublingual
- Sub Cutaneous
- Intravenous
By Treatment:
- Antihistamines
- Decongestants
- Nasal Corticosteroids
- Allergen Immunotherapy
- Leukotriene Receptor Antagonists
By Distribution Channel:
- Hospital Pharmacies
- Supermarkets/Hypermarkets
- Online Pharmacies
- Retail Pharmacies
- Speciality Clinics
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- The Middle East and Africa (MEA)
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube